Who
Thomas Edward Hamilton
Director
Company insider
Files Form 4 as: Director, Larimar Therapeutics; Director, Annaly Capital Management.
In numbers
- Trades disclosed
- 31
- Buys
- 7
- Sells
- 1
- Bought
- $5.4M
- Sold
- $734K
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 17 May 2019
- Last trade
- 6 Jul 2026
- Last filed
- 8 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Jul 2026filed 8 Jul 2026 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Bought | $167K50,000 at $3.34 | filing |
| 6 Jul 2026filed 8 Jul 2026 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Bought | $167K50,000 at $3.34 | filing |
| 10 Jun 2026filed 12 Jun 2026 | NLY Annaly Capital Managementoption or derivative · REITs | SEC FORM 4 Code A | —8,641 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | NLY Annaly Capital Managementoption or derivative · REITs | SEC FORM 4 Code A | —8,641 at $0.00 | filing |
| 19 May 2026filed 20 May 2026 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,150 at $0.00 | filing |
| 19 May 2026filed 20 May 2026 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,150 at $0.00 | filing |
| 27 Feb 2026filed 2 Mar 2026 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Bought | $500K100,000 at $5.00 | filing |
| 27 Feb 2026filed 2 Mar 2026 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Bought | $500K100,000 at $5.00 | filing |
| 14 May 2025filed 15 May 2025 | NLY Annaly Capital Managementoption or derivative · REITs | SEC FORM 4 Code A | —8,961 at $0.00 | filing |
| 13 May 2025filed 14 May 2025 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 29 May 2024filed 31 May 2024 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 15 May 2024filed 17 May 2024 | NLY Annaly Capital Managementoption or derivative · REITs | SEC FORM 4 Code A | —8,583 at $0.00 | filing |
| 16 Feb 2024filed 31 May 2024 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Bought | $500K57,208 at $8.74 | filing |
| 17 May 2023filed 19 May 2023 | NLY Annaly Capital Managementoption or derivative · REITs | SEC FORM 4 Code A | —8,167 at $0.00 | filing |
| 9 May 2023filed 11 May 2023 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,300 at $0.00 | filing |
| 16 Sep 2022filed 20 Sep 2022 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Bought | $1000K317,460 at $3.15 | filing |
| 18 May 2022filed 20 May 2022 | NLY Annaly Capital Managementoption or derivative · REITs | SEC FORM 4 Code A | —24,372 at $0.00 | filing |
| 10 May 2022filed 12 May 2022 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,300 at $0.00 | filing |
| 30 Jun 2021filed 2 Jul 2021 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Bought | $496K56,710 at $8.75 | filing |
| 19 May 2021filed 21 May 2021 | NLY Annaly Capital Managementoption or derivative · REITs | SEC FORM 4 Code A | —15,609 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.